In the second half of this two-part webinar, find out how to optimize your CAR-T production methods by maximizing transduction efficiency.

Chimeric Antigen Receptor (CAR)-T cell therapy is a promising development in cancer immunotherapy, but method optimization is necessary to produce the cells at scale. In part 2 of this two-part webinar, we will show how to optimize your CAR-T production methods by maximizing transduction efficiency with Physiologix XF serum replacement. In this video, we will:

  • Introduce Physiologix XF serum replacement
  • Share transduction efficiency data of T cells from the lab of Dr. Roddy O’Connor of UPENN
Our speaker
Alyssa Master, Ph.D.
Alyssa Master, Ph.D.

Nucleus Biologics

Dr. Alyssa Master is the VP of Sales Enablement and Customer Experience at Nucleus Biologics. She is a subject matter expert on cell culture media solutions, primarily on the development of custom cell culture media. Dr. Master has ten years of laboratory research experience, including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. During her numerous fellowships, Dr. Master developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Dr. Master earned her Ph.D. in Biomedical Engineering from Case Western Reserve University. Read more


Welcome to Nucleus Biologics, the leaders in precision cell culture. It's me again, Alyssa Master, Director of Science and Applications at Nucleus. Today we'll be sharing some research performed in the lab of Dr. Roddy O'Connor, Senior Research Investigator at UPENN Center for Cellular Immunotherapies. Today, we're going to talk about enhancing transduction efficiency of primary T cells using the newest addition to our line of media supplements called Physiologix xeno-free human growth factor concentrate. Physiologix is a fully xeno-free serum replacement that is extracted from transfusion-grade donor material through a proprietary manufacturing process. This process yields a growth factor concentrate that is comprised of the right growth factors for your cells in the most physiologically relevant ratio. For more information on how Physiologix addresses your cell culture needs, please view our other webinars, and visit


Here we show that Physiologix is an enhancer of transduction efficiency. Bulk T cells from a healthy donor were cultured in RPMI containing either 10% FBS as a control or 2% Physiologix. Cells were then activated for 3 days prior to the lentiviral addition of a GFP reporter plasmid, and four days later GFP expression was examined using flow cytometry as a readout of transduction efficiency. As you can see, 94.1% of cells cultured in Physiologix were successfully transduced as compared to 74% of control cells. This shows that something as easy as changing your media components could improve the efficiency of your cell therapy development process, saving you both time and money.


If you are interested in learning more about the functionality, cost, and reduced regulatory risk associated with Physiologix, please stay tuned for future presentations. If you're interested in sampling Physiologix, please email [email protected] or call 858-251-2013 to speak to an application scientist. And, as always, for more information, please visit Thank you for your time and we hope you enjoyed learning about Physiologix.

Share this article